# Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

> **NCT02136511** · — · APPROVED_FOR_MARKETING · sponsor: **Gilead Sciences**

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02136511
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02136511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02136511, "Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02136511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*